Next, we used flow cytometry analyzer to detect cell cycle and apoptosis, in order to further confirm that HSP90 inhibitor 17AAG combined with protein nucleocapsid inhibitor LMB can enhance the killing ability when targeting CML cells. This evidence concerns the gene HSP90AA1 and chronic myelogenous leukemia, BCR-ABL1 positive.